ABIOYE ARAWOLE: Open Payments
NPI 1609584481 · MANSFIELD, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,018 in 54 payments from 8 companies in 2025. Trend: 2023 $332 · 2024 $1,078 · 2025 $1,018
Food & beverage: $1,018
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 10 | $318 |
| Janssen Pharmaceuticals, Inc | 10 | $201 |
| ABBVIE INC. | 18 | $153 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $109 |
| Otsuka America Pharmaceutical, Inc. | 5 | $98 |
| E.R. Squibb & Sons, L.L.C. | 4 | $73 |
| Biogen, Inc. | 2 | $35 |
| Axsome Therapeutics, Inc. | 1 | $33 |
Products named: ARISTADA, VRAYLAR, INVEGA SUSTENNA, CAPLYTA, REXULTI, LYBALVI, SPRAVATO, COBENFY.
Industry payments across TX — which companies pay providers there.
